Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
How to improve the prevention of chemotherapy-induced nausea and vomiting? The French NAVI study.
Vanbockstael J, Coquan E, Gouerant S, Allouache D, Faveyrial A, Noal S, Delcambre C, Galais MP, Héron JF, Lefebvre AC, Sevin E, Hrab I, Polycarpe F, André M, Kaluzinski L, Gervais R, Gunzer K, Vié B, Saucier G, Lemenand N, Grellard JM, Clarisse B, Dugué AE, Joly F. Vanbockstael J, et al. Among authors: dugue ae. Support Care Cancer. 2016 Mar;24(3):1131-8. doi: 10.1007/s00520-015-2882-7. Epub 2015 Aug 14. Support Care Cancer. 2016. PMID: 26268784
Optimisation of chemotherapy prescription and preparation in an ambulatory unit: Validation of the OPTIMA program.
Dos Santos M, Lequesne J, Dugué AE, Grellard JM, Ory C, Jaffré S, Lavergne K, Lelaidier A, Laroche L, Divanon F, Delcambre C, Galais MP, Clarisse B, Faveyrial A. Dos Santos M, et al. Among authors: dugue ae. Eur J Cancer Care (Engl). 2019 May;28(3):e13015. doi: 10.1111/ecc.13015. Epub 2019 Feb 20. Eur J Cancer Care (Engl). 2019. PMID: 30790365
Utility of serum anti-cetuximab immunoglobulin E levels to identify patients at a high risk of severe hypersensitivity reaction to cetuximab.
Dupont B, Mariotte D, Dugué AE, Clarisse B, Grellard JM, Babin E, Chauffert B, Dakpé S, Moldovan C, Bouhier-Leporrier K, Reimund JM, Di Fiore F, Zanetta S, Mailliez A, Do P, Peytier A, Galais MP, Florescu C, Schott R, Le Mauff B, Gervais R. Dupont B, et al. Among authors: dugue ae. Br J Clin Pharmacol. 2017 Mar;83(3):623-631. doi: 10.1111/bcp.13140. Epub 2016 Oct 24. Br J Clin Pharmacol. 2017. PMID: 27662818 Free PMC article.
Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol.
Lesueur P, Lequesne J, Grellard JM, Dugué A, Coquan E, Brachet PE, Geffrelot J, Kao W, Emery E, Berro DH, Castera L, Goardon N, Lacroix J, Lange M, Capel A, Leconte A, Andre B, Léger A, Lelaidier A, Clarisse B, Stefan D. Lesueur P, et al. BMC Cancer. 2019 Mar 4;19(1):198. doi: 10.1186/s12885-019-5413-y. BMC Cancer. 2019. PMID: 30832617 Free PMC article.
Renal insufficiency is the leading cause of double maintenance (bevacizumab and pemetrexed) discontinuation for toxicity to advanced non-small cell lung cancer in real world setting.
Sassier M, Dugué AE, Clarisse B, Lesueur P, Avrillon V, Bizieux-Thaminy A, Auliac JB, Kaluzinski L, Tillon J, Robinet G, Le Caer H, Monnet I, Madroszyk A, Boza G, Falchero L, Fournel P, Egenod T, Toffart AC, Leiber N, Do P, Gervais R. Sassier M, et al. Among authors: dugue ae. Lung Cancer. 2015 Aug;89(2):161-6. doi: 10.1016/j.lungcan.2015.05.005. Epub 2015 May 15. Lung Cancer. 2015. PMID: 26037036
REBECA: a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain metastasis from solid tumours.
Lévy C, Allouache D, Lacroix J, Dugué AE, Supiot S, Campone M, Mahe M, Kichou S, Leheurteur M, Hanzen C, Dieras V, Kirova Y, Campana F, Le Rhun E, Gras L, Bachelot T, Sunyach MP, Hrab I, Geffrelot J, Gunzer K, Constans JM, Grellard JM, Clarisse B, Paoletti X. Lévy C, et al. Among authors: dugue ae. Ann Oncol. 2014 Dec;25(12):2351-2356. doi: 10.1093/annonc/mdu465. Epub 2014 Oct 1. Ann Oncol. 2014. PMID: 25274615 Free article. Clinical Trial.
Staging the axilla in breast cancer patients with ¹⁸F-FDG PET: how small are the metastases that we can detect with new generation clinical PET systems?
Bellevre D, Blanc Fournier C, Switsers O, Dugué AE, Levy C, Allouache D, Desmonts C, Crouet H, Guilloit JM, Grellard JM, Aide N. Bellevre D, et al. Among authors: dugue ae. Eur J Nucl Med Mol Imaging. 2014 Jun;41(6):1103-12. doi: 10.1007/s00259-014-2689-7. Epub 2014 Feb 22. Eur J Nucl Med Mol Imaging. 2014. PMID: 24562642 Free PMC article.
Identification of predictive factors of response to the BH3-mimetic molecule ABT-737: an ex vivo experiment in human serous ovarian carcinoma.
Lheureux S, N'Diaye M, Blanc-Fournier C, Dugué AE, Clarisse B, Dutoit S, Giffard F, Abeilard E, Briand M, Labiche A, Grellard JM, Crouet H, Martin S, Joly F, Poulain L. Lheureux S, et al. Among authors: dugue ae. Int J Cancer. 2015 Mar 1;136(5):E340-50. doi: 10.1002/ijc.29104. Epub 2014 Aug 8. Int J Cancer. 2015. PMID: 25066666 Free article.
38 results